MIBio engages leading experts from industry and academia in a discussion on how the latest molecular interaction based discoveries can be exploited in biopharmaceutical formulation to deliver more effective, patient-friendly, and safer therapeutic products.

The 2024 meeting will primarily focus on subcutaneous delivery. In spite of advances in other dosage forms and routes of administration over the last decade, subcutaneous products dominate the biopharmaceutical pipelines of Pharma and Biotech companies due to their simplicity, reliability and suitability for self-administration. The trend is further fuelled by continuous improvements of delivery devices and their digital connectivity. The state-of-the-art of the subcutaneous delivery will be discussed at MIBio 2024 as well as possible future trends. However, they will also focus on other challenges including bioavailability, and ways of addressing them.

Come and talk to us at our booth. We can't wait to see you!